Get the Stockscreener App
8.14
0.97%
-0.08
After Hours:
8.12
-0.02
-0.25%
Gyre Therapeutics Inc stock is traded at $8.14, with a volume of 61,069.
It is down -0.97% in the last 24 hours and up +13.69% over the past month.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
See More
Previous Close:
$8.22
Open:
$8.29
24h Volume:
61,069
Relative Volume:
0.29
Market Cap:
$763.19M
Revenue:
$106.66M
Net Income/Loss:
$15.16M
P/E Ratio:
87.06
EPS:
0.0935
Net Cash Flow:
$6.37M
1W Performance:
+13.21%
1M Performance:
+13.69%
6M Performance:
-32.05%
1Y Performance:
-23.78%
1-Day Range:
$8.00
$8.29
1-Week Range:
$6.62
$8.30
52-Week Range:
$6.11
$19.00
Gyre Therapeutics Inc Stock (GYRE) Company Profile
Name
Gyre Therapeutics Inc
Sector
Industry
Phone
(619) 949-3681
Address
12770 HIGH BLUFF DRIVE, SUITE 150, SAN DIEGO
Compare GYRE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GYRE
Gyre Therapeutics Inc
|
8.14 | 746.60M | 106.66M | 15.16M | 6.37M | 0.0935 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-25 | Initiated | Noble Capital Markets | Outperform |
| Apr-29-21 | Resumed | Stephens | Overweight |
| Feb-10-21 | Initiated | Piper Sandler | Overweight |
| May-21-20 | Initiated | Raymond James | Outperform |
| Jan-04-19 | Initiated | Oppenheimer | Outperform |
| Feb-12-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Feb-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Dec-08-17 | Initiated | B. Riley FBR, Inc. | Buy |
| Jun-12-17 | Initiated | Chardan Capital Markets | Buy |
| Jun-06-17 | Initiated | Ladenburg Thalmann | Buy |
| Jun-30-16 | Initiated | Rodman & Renshaw | Buy |
View All
Gyre Therapeutics Inc Stock (GYRE) Latest News
How moving averages guide Gyre Therapeutics Inc. trading2025 Market WrapUp & Free Technical Confirmation Trade Alerts - Newser
Is Gyre Therapeutics Inc. reversing from oversold territoryJuly 2025 Volume & Expert Approved Momentum Ideas - Newser
Understanding Gyre Therapeutics Inc.’s price movement2025 Trading Volume Trends & Reliable Price Action Trade Plans - Newser
How to build a custom watchlist for Gyre Therapeutics Inc.Gold Moves & Growth Focused Stock Pick Reports - Newser
Using RSI to spot recovery in Gyre Therapeutics Inc.Analyst Upgrade & Risk Controlled Daily Trade Plans - Newser
Using AI based signals to follow Gyre Therapeutics Inc.Product Launch & Fast Exit and Entry Strategy Plans - Newser
Gyre Therapeutics Inc. stock trendline breakdownJuly 2025 Setups & Trade Opportunity Analysis Reports - Newser
Can Gyre Therapeutics Inc. be recession proofEarnings Overview Report & Low Risk High Win Rate Stock Picks - thegnnews.com
What Technical Tools Say About Gyre Therapeutics Inc. RecoveryQuarterly Performance Summary & Weekly Top Gainers Alerts - metal.it
Published on: 2025-08-16 06:42:22 - Newser
Is Gyre Therapeutics Inc. meeting your algorithmic filter criteriaMarket Growth Report & Community Verified Trade Alerts - Newser
Can Gyre Therapeutics Inc. recover in the next quarterQuarterly Profit Summary & Reliable Trade Execution Plans - Newser
Is Gyre Therapeutics Inc. a defensive stockPortfolio Risk Summary & Free Real-Time Volume Trigger Notifications - thegnnews.com
Price momentum metrics for Gyre Therapeutics Inc. explainedMarket Performance Summary & Daily Entry Point Alerts - Newser
How to use a screener to detect Gyre Therapeutics Inc. breakoutsEarnings Risk Report & Detailed Earnings Play Strategies - Newser
Tools to assess Gyre Therapeutics Inc.’s risk profileWeekly Trade Review & Daily Chart Pattern Signals - Newser
When is the best time to exit Gyre Therapeutics Inc.Portfolio Risk Report & Comprehensive Market Scan Insights - Newser
What makes Gyre Therapeutics Inc. stock price move sharplyQuarterly Trade Summary & High Win Rate Trade Tips - Newser
Published on: 2025-08-15 14:47:47 - Newser
News impact scoring models applied to Gyre Therapeutics Inc.Earnings Growth Report & Stepwise Entry/Exit Trade Alerts - Newser
Gyre Therapeutics Reports Q2 2025 Earnings and Strategic Updates - TipRanks
Using flow based indicators on Gyre Therapeutics Inc.Swing Trade & Expert Curated Trade Setups - Newser
What Is The Outlook For Bicara Therapeutics Inc (NASDAQ: BCAX) Like For Short-Term? - stocksregister.com
US Undiscovered Gems 3 Promising Small Caps with Strong Potential - simplywall.st
Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Down on Disappointing Earnings - Defense World
Gyre Therapeutics Inc. stock trend outlook and recovery pathWatchlist Summary for Active Day Traders - Newser
H.C. Wainwright Initiates a Buy Rating on Gyre Therapeutics (GYRE) - The Globe and Mail
Gyre Therapeutics Misses Estimates And Swaps In A New CEO - Finimize
Gyre Therapeutics Inc. Added to Custom Quant Screener TodayRisk Managed Trade Playbook Analysis - beatles.ru
GYRE THERAPEUTICS, INC. SEC 10-Q Report - TradingView
Can you recover from losses in Gyre Therapeutics Inc.Free Reliable Investment Entry Point Signals - Newser
Gyre Therapeutics' Q2 revenue misses estimates - MarketScreener
Gyre Therapeutics Hits Major Milestone: Phase 3 Liver Drug Success Powers $128M Revenue Outlook - Stock Titan
Sector Rotation Brings Gyre Therapeutics Inc. Into FocusTriple Return Setup With Risk Control Explained - beatles.ru
Published on: 2025-08-11 05:27:12 - Newser
Why Gyre Therapeutics Inc. stock attracts strong analyst attentionReal-Time Entry Signals for Top Stocks - Newser
Gyre Therapeutics Inc Stock (GYRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Gyre Therapeutics Inc Stock (GYRE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ma Songjiang | President |
May 28 '25 |
Sale |
10.07 |
558 |
5,619 |
2,806,084 |
| Ma Songjiang | President |
May 22 '25 |
Sale |
10.97 |
2,000 |
21,940 |
2,808,824 |
| Ma Songjiang | President |
May 23 '25 |
Sale |
10.24 |
182 |
1,864 |
2,808,642 |
| Ma Songjiang | President |
May 20 '25 |
Sale |
11.25 |
2,000 |
22,500 |
2,812,824 |
| Ma Songjiang | President |
May 21 '25 |
Sale |
10.83 |
2,000 |
21,660 |
2,810,824 |
| Ma Songjiang | President |
May 16 '25 |
Sale |
11.31 |
2,000 |
22,620 |
2,816,824 |
| Ma Songjiang | President |
May 19 '25 |
Sale |
11.11 |
2,000 |
22,220 |
2,814,824 |
| Ma Songjiang | President |
May 15 '25 |
Sale |
10.68 |
2,000 |
21,360 |
2,818,824 |
| Ma Songjiang | President |
May 14 '25 |
Sale |
11.30 |
20 |
226 |
2,820,824 |
| Ye Weiguo | Chief Operating Officer |
Apr 01 '25 |
Option Exercise |
0.75 |
50,000 |
37,500 |
700,000 |
0.41%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):